Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 150

1.

Effect of specimen processing, growth supplement, and different metabolic population on Mycobacterium tuberculosis laboratory diagnosis.

Srivastava S, Chapagain M, Gumbo T.

PLoS One. 2020 Apr 3;15(4):e0230927. doi: 10.1371/journal.pone.0230927. eCollection 2020.

PMID:
32243457
2.

Dynamic imaging in patients with tuberculosis reveals heterogeneous drug exposures in pulmonary lesions.

Ordonez AA, Wang H, Magombedze G, Ruiz-Bedoya CA, Srivastava S, Chen A, Tucker EW, Urbanowski ME, Pieterse L, Fabian Cardozo E, Lodge MA, Shah MR, Holt DP, Mathews WB, Dannals RF, Gobburu JVS, Peloquin CA, Rowe SP, Gumbo T, Ivaturi VD, Jain SK.

Nat Med. 2020 Feb 17. doi: 10.1038/s41591-020-0770-2. [Epub ahead of print]

PMID:
32066976
3.

Repurposing drugs for treatment of Mycobacterium abscessus: a view to a kill.

Gumbo T, Cirrincione K, Srivastava S.

J Antimicrob Chemother. 2020 Feb 4. pii: dkz523. doi: 10.1093/jac/dkz523. [Epub ahead of print]

PMID:
32016429
4.

A Human Lung Challenge Model to Evaluate the Safety and Immunogenicity of PPD and Live BCG.

Davids M, Pooran A, Hermann C, Mottay L, Thompson F, Cardenas J, Gu J, Koeuth T, Meldau R, Limberis J, Gina P, Srivastava S, Calder B, Esmail A, Tomasicchio M, Blackburn J, Gumbo T, Dheda K.

Am J Respir Crit Care Med. 2019 Dec 20. doi: 10.1164/rccm.201908-1580OC. [Epub ahead of print]

PMID:
31860339
5.

Pharmacokinetics and other risk factors for kanamycin-induced hearing loss in patients with multi-drug resistant tuberculosis.

Ghafari N, Court R, Chirehwa MT, Wiesner L, Petersen L, Maartens G, Gumbo T, McIlleron H, Ramma L.

Int J Audiol. 2020 Mar;59(3):219-223. doi: 10.1080/14992027.2019.1690170. Epub 2019 Nov 18.

PMID:
31739701
6.

Duration of pretomanid/moxifloxacin/pyrazinamide therapy compared with standard therapy based on time-to-extinction mathematics.

Srivastava S, Deshpande D, Magombedze G, van Zyl J, Cirrincione K, Martin K, Bendet P, Berg A, Hanna D, Romero K, Hermann D, Gumbo T.

J Antimicrob Chemother. 2020 Feb 1;75(2):392-399. doi: 10.1093/jac/dkz460.

7.

Integrating pharmacokinetics and pharmacodynamics in operational research to End TB.

Alffenaar JC, Gumbo T, Dooley KE, Peloquin CA, McIlleron H, Zagorski A, Cirillo DM, Heysell SK, Silva DR, Migliori GB.

Clin Infect Dis. 2019 Sep 27. pii: ciz942. doi: 10.1093/cid/ciz942. [Epub ahead of print]

PMID:
31560376
8.

The Lancet Respiratory Medicine Commission: 2019 update: epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant and incurable tuberculosis.

Dheda K, Gumbo T, Maartens G, Dooley KE, Murray M, Furin J, Nardell EA, Warren RM; Lancet Respiratory Medicine drug-resistant tuberculosis Commission group.

Lancet Respir Med. 2019 Sep;7(9):820-826. doi: 10.1016/S2213-2600(19)30263-2. Review.

PMID:
31486393
9.

Dosing tuberculosis drugs in young children: the road ahead.

Pasipanodya JG, Gumbo T.

Lancet Child Adolesc Health. 2019 Sep;3(9):590-592. doi: 10.1016/S2352-4642(19)30180-4. Epub 2019 Jul 16. No abstract available.

PMID:
31324599
10.

Optimizing ethambutol dosing among HIV/tuberculosis co-infected patients: a population pharmacokinetic modelling and simulation study.

Mehta K, Ravimohan S, Pasipanodya JG, Srivastava S, Modongo C, Zetola NM, Weissman D, Ivaturi V, Gumbo T, Bisson GP, Vinnard C.

J Antimicrob Chemother. 2019 Oct 1;74(10):2994-3002. doi: 10.1093/jac/dkz265.

PMID:
31273386
11.

Quantitative assessment of the activity of antituberculosis drugs and regimens.

Chirehwa MT, Velásquez GE, Gumbo T, McIlleron H.

Expert Rev Anti Infect Ther. 2019 Jun;17(6):449-457. doi: 10.1080/14787210.2019.1621747. Epub 2019 May 30. Review.

PMID:
31144539
12.

Minocycline treatment for pulmonary Mycobacterium avium complex disease based on pharmacokinetics/pharmacodynamics and Bayesian framework mathematical models.

Ruth MM, Magombedze G, Gumbo T, Bendet P, Sangen JJN, Zweijpfenning S, Hoefsloot W, Pennings L, Koeken VACM, Wertheim HFL, Lee PS, van Ingen J, Deshpande D.

J Antimicrob Chemother. 2019 Jul 1;74(7):1952-1961. doi: 10.1093/jac/dkz143.

PMID:
31039251
13.

Detectable prednisolone is delayed in pericardial fluid, compared with plasma of patients with tuberculous pericarditis: A pilot study.

Shenje J, Gumbo T, Wiesner L, Ntsekhe M, Mayosi B, Ross I.

Int J Cardiol Heart Vasc. 2019 Jan 11;22:105-110. doi: 10.1016/j.ijcha.2018.12.008. eCollection 2019 Mar.

14.

Once-a-week tigecycline for the treatment of drug-resistant TB.

Deshpande D, Magombedze G, Srivastava S, Bendet P, Lee PS, Cirrincione KN, Martin KR, Dheda K, Gumbo T.

J Antimicrob Chemother. 2019 Jun 1;74(6):1607-1617. doi: 10.1093/jac/dkz061.

PMID:
30820554
15.

Spatial Network Mapping of Pulmonary Multidrug-Resistant Tuberculosis Cavities Using RNA Sequencing.

Dheda K, Lenders L, Srivastava S, Magombedze G, Wainwright H, Raj P, Bush SJ, Pollara G, Steyn R, Davids M, Pooran A, Pennel T, Linegar A, McNerney R, Moodley L, Pasipanodya JG, Turner CT, Noursadeghi M, Warren RM, Wakeland E, Gumbo T.

Am J Respir Crit Care Med. 2019 Aug 1;200(3):370-380. doi: 10.1164/rccm.201807-1361OC.

16.

Minocycline Immunomodulates via Sonic Hedgehog Signaling and Apoptosis and Has Direct Potency Against Drug-Resistant Tuberculosis.

Deshpande D, Pasipanodya JG, Srivastava S, Martin KR, Athale S, van Zyl J, Antiabong J, Koeuth T, Lee PS, Dheda K, Gumbo T.

J Infect Dis. 2019 Feb 23;219(6):975-985. doi: 10.1093/infdis/jiy587.

PMID:
30597040
17.

Linezolid-based Regimens for Multidrug-resistant Tuberculosis (TB): A Systematic Review to Establish or Revise the Current Recommended Dose for TB Treatment.

Bolhuis MS, Akkerman OW, Sturkenboom MGG, Ghimire S, Srivastava S, Gumbo T, Alffenaar JC.

Clin Infect Dis. 2018 Nov 28;67(suppl_3):S327-S335. doi: 10.1093/cid/ciy625.

PMID:
30496467
18.

Efficacy Versus Hepatotoxicity of High-dose Rifampin, Pyrazinamide, and Moxifloxacin to Shorten Tuberculosis Therapy Duration: There Is Still Fight in the Old Warriors Yet!

Srivastava S, Deshpande D, Magombedze G, Gumbo T.

Clin Infect Dis. 2018 Nov 28;67(suppl_3):S359-S364. doi: 10.1093/cid/ciy627.

19.

Transformation Morphisms and Time-to-Extinction Analysis That Map Therapy Duration From Preclinical Models to Patients With Tuberculosis: Translating From Apples to Oranges.

Magombedze G, Pasipanodya JG, Srivastava S, Deshpande D, Visser ME, Chigutsa E, McIlleron H, Gumbo T.

Clin Infect Dis. 2018 Nov 28;67(suppl_3):S349-S358. doi: 10.1093/cid/ciy623.

20.

The Sterilizing Effect of Intermittent Tedizolid for Pulmonary Tuberculosis.

Srivastava S, Deshpande D, Nuermberger E, Lee PS, Cirrincione K, Dheda K, Gumbo T.

Clin Infect Dis. 2018 Nov 28;67(suppl_3):S336-S341. doi: 10.1093/cid/ciy626.

Supplemental Content

Loading ...
Support Center